Avanza Fonder AB Makes New $1.86 Million Investment in Hologic, Inc. (NASDAQ:HOLX)

Avanza Fonder AB acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 25,810 shares of the medical equipment provider's stock, valued at approximately $1,861,000.

A number of other institutional investors have also made changes to their positions in HOLX. Benson Investment Management Company Inc. bought a new position in shares of Hologic in the 4th quarter valued at about $4,832,000. Clean Yield Group increased its position in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after buying an additional 7,266 shares during the last quarter. GAMMA Investing LLC raised its stake in Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock valued at $312,000 after buying an additional 582 shares during the period. Janus Henderson Group PLC lifted its position in shares of Hologic by 2.9% in the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after buying an additional 800 shares during the last quarter. Finally, Versor Investments LP bought a new position in shares of Hologic during the 3rd quarter worth approximately $1,677,000. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Monday, January 13th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Hologic has a consensus rating of "Moderate Buy" and an average target price of $88.92.

Hologic Stock Performance

NASDAQ:HOLX traded down $0.24 on Friday, reaching $69.73. 6,395,054 shares of the company's stock were exchanged, compared to its average volume of 2,046,611. The firm has a market cap of $15.82 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a fifty day simple moving average of $74.84 and a 200-day simple moving average of $78.41. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 earnings per share. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.